2X1:ETR
Abivax SA
78,45 €
arrow_downward
-0,70%(-0,55) 1D
12-окт., 17:35:43 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2X1...
Open
79,25 €
High
79,25 €
Low
77,50 €
Mkt. cap
6,71 млд
Avg. vol.
1,81 миң
Volume
921,00
52-wk high
137,40 €
52-wk low
60,85 €
EPS
-5,20 €
No. of employees
98
Open
79,25 €
High
79,25 €
Low
77,50 €
Mkt. cap
6,71 млд
Avg. vol.
1,81 миң
Volume
921,00
52-wk high
137,40 €
52-wk low
60,85 €
EPS
-5,20 €
No. of employees
98
News stories
From web sources and news partners
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com